Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy

Exclusion Criteria

• •Patients who can not benefit from bevacizumab for the following reasons:
• •* Symptomatic cerebral or tumor hemorrhage
• •* Karnofsky Index less than 50% or
• •Patients already treated with an antiangiogenic molecule or Gliadel (diagnosis and recurrence).
• •Coagulation disorders in case of injectable treatment (especially for avastin),
• •Contraindications known to the MRI: Pace Makers, foreign bodies intraocular, electrodes ...
• •Uncontrolled severe concomitant pathology, including another evolving cancer (with the exception of operative cutaneous tumors, in situ cancer of the cervix or breast treated).
• •Uncontrolled Infection
• •Uncontrolled hypertension (PAS\> 160 mm Hg) despite optimized treatment
• •Coronary artery disease or unstable arterial disease. Evolutionary aneurysm.
• •Myocardial infarction dating from less than 6 months.
• •Peripheral arterial or cerebrovascular accident occurring less than 6 months.
• •Heart Failure\> grade II NYHA
• •Hemorrhagic Disease (Hemophilia, Willebrandt ...)
• •Nephrotic syndrome with proteinuria\> 2 g / 24 h
• •History of haemoptysis dating less than 1 month.
• •Pulmonary embolism dating less than 1 month.
• •Surgical intervention (other than craniotomy or stereotactic biopsy) dating less than one month or essential and predictable surgery.
• •History of digestive fistula or intestinal perforation with resolution less than 6 months.
• •Hypersensitivity to bevacizumab or to any of the excipients mentioned in Composition.
• •Hypersensitivity to Chinese hamster ovary (CHO) cells or to other human or humanized recombinant antibodies.
• •Severe Myelosuppression
• •Pregnant or nursing. Contraception should be prescribed if necessary during treatment.
• •Persons deprived of liberty or placed under safeguard of justice (guardianship or curatorship),
• •Subject involved in another search including an exclusion period still in progress at pre-inclusion
• •Patient refusing to participate in the study